TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19720897
Drug: Etoposide-carboplatin (etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide-carboplatin (etoposide 100 mg/m² on days 1-3; carboplatin AUC 5 on day 1)
Study: 11919238
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (chemotherapy, hormonal therapy, or both) for node-positive disease
Study: 11919238
Drug: Combined multidrug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined multidrug chemotherapy plus tamoxifen for node-positive disease
Study: 11919238
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy for node-negative disease
Study: 11919238
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1995
Study: 11919238
Drug: Both tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both tamoxifen and combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1995
Study: 11919238
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1987
Study: 11919238
Drug: Both tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both tamoxifen and combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1987
Study: 9598218
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of fenfluramine (FEN)
Study: 8185343
Drug: FUT-187 (sepimostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUT-187 (sepimostat mesilate) 300 mg/day
Study: 8185343
Drug: FUT-187 (sepimostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUT-187 (sepimostat mesilate) 400 mg/day
Study: 2820312
Drug: Vindesine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (3 mg/m2 X 3) plus cisplatin (80‐120 mg/m2)
Study: 2820312
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (8 mg/m2) plus vindesine (2 mg/m2 X 3) plus cisplatin (80‐120 mg/m2)
Study: 30001547
Drug: Phonological Reading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonological Reading and Writing Remediation Program (24 cumulative sessions, twice a week, 30 min each)
Study: 22495941
Drug: Escitalopram monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram monotherapy (escitalopram and placebo)
Study: 22495941
Drug: Antidepressant combination
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant combination (venlafaxine-XR and mirtazapine or escitalopram and bupropion-SR)
Study: 22495941
Drug: MDD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDD with concurrent SUD
Study: 22495941
Drug: MDD without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDD without concurrent SUD
Study: 12810991
Drug: Iontophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis with alternating current (AC) combined with anticholinergic drugs
Study: 10380089
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone (3 x 500 microg)
Study: 10380089
Drug: Systemic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic dexamethasone (0.5 mg/kg/day)
Study: 7483814
Drug: Recombinant staphylokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant staphylokinase (10 mg intravenous infusion over 30 min)
Study: 1682544
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg orally per day for 10 days
Study: 1682544
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg orally per day for 20 or 30 days
Study: 1682544
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg orally per day
Study: 1682544
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg orally per day for at least 20 days
Study: 31997084
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg plus 300 mg green tea extract
Study: 31997084
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg plus 600 mg green tea extract
Study: 31997084
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg alone
Study: 30471953
Drug: DTaP-IPV-HB-PRP-T co-administered
Normalized name: Hib (PRP-T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-HB-PRP-T co-administered with MenACWY-TT vaccine (Group A; n=104)
Study: 30471953
Drug: DTaP-IPV-HB-PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-HB-PRP-T vaccine alone (Group B; n=105)
Study: 30471953
Drug: MenACWY-TT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT vaccine alone (Group C; n=103)
Study: 15257733
Drug: Ultrasonic instrumentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic instrumentation + application of 8.5% w/w doxycycline gel (Atridox)
Study: 9193198
Drug: L-745,870 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-745,870 (15 mg/d)
Study: 9193198
Drug: L-745,870
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-745,870
Study: 1539847
Drug: morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (0.1 mg.kg‐1, iv)
Study: 1539847
Drug: ketorolac (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac (0.9 mg.kg‐1, iv)
Study: 18278698
Drug: Chemotherapy (specifics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (specifics not provided)
Study: 18278698
Drug: Pharmacogenetics and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetics and pharmacogenomics (individualisation of therapy)
Study: 12618256
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg sublingual misoprostol 3 h prior to vacuum aspiration (VA)
Study: 8608073
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml 0.5% plain bupivacaine
Study: 8608073
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml 0.75% hyperbaric bupivacaine premixed in 8.25% glucose
Study: 2669036
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose total body irradiation (STBI) - 10 Gy at a 4.5 cGy/min dose rate, 8 Gy to the lungs
Study: 23362
Drug: 1% selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% selenium disulfid suspension
Study: 27932871
Drug: FFR-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFR-guided therapy
Study: 27932871
Drug: Angiography-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiography-guided therapy
Study: 20975109
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein and leucine supplementation (19.7 g of whey protein and 6.2 g of leucine)
Study: 18552703
Drug: Guanfacine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (3 mg/day maximum dose)
Study: 7481023
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Initial dose of 8 ml bupivacaine 0.25% (20 mg) with epinephrine 1/200,000 and 50 micrograms fentanyl followed by continuous infusion of 8 ml/h bupivacaine 0.125% (10 mg/h) with epinephrine 1/400,000
Study: 7481023
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Initial dose of 10 ml bupivacaine 0.125% (12.5 mg) with epinephrine 1/400,000 and 50 micrograms fentanyl followed by continuous infusion of 12 ml/h bupivacaine 0.0625% (7.5 mg/h) with epinephrine 1/800,000 and 12 micrograms/h fentanyl
Study: 7481023
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: Initial dose same as group A, but maintenance through a patient‐controlled (PCA) system with 5 ml bupivacaine 0.25% (12.5 mg) and epinephrine 1/200,000 set for a minimum interval of 1 h
Study: 2196631
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nortriptyline (NT) at a plasma level of 80 +/- 20 ng/ml, monitored weekly over 8 weeks.
Study: 22419
Drug: Nabilone (2-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (2-mg single doses)
Study: 22419
Drug: Diazepam (5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5-mg single doses)
Study: 30999915
Drug: Artesunate-mefloquine (ASMQ)
Normalized name: artesunate and mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-mefloquine (ASMQ) fixed dose combination, 25/55 mg AS/MQ administered once a day for 3 days
Study: 29880750
Drug: Glutamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (30 g) with low-nutrient drink (beef soup; 18 kcal)
Study: 29880750
Drug: Glutamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (30 g) with high-nutrient drink (75 g dextrose; 255 kcal)
Study: 27521811
Drug: Abstinence Reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence Reinforcement Therapy (ART) which includes cognitive-behavioral telephone counseling (TC), telemedicine clinic for nicotine replacement (NRT), and mobile contingency management (mCM)
Study: 25490675
Drug: H1/IC31 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1/IC31 vaccine
Study: 17686832
Drug: Salba (37
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salba (37 ± 4 g/day)
Study: 15596419
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU, 80 mg bid)
Study: 11983659
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg x kg(‐1) ketorolac (maximum of 15 mg) six hourly postoperatively for 36 hr
Study: 11983659
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg x kg(‐1) ketorolac
Study: 9818634
Drug: Citalopram 10
Normalized name: citalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 10 or 15 mg/day
Study: 4785
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate (50 micrograms in each nostril four times a day)
Study: 4785
Drug: Placebo aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aerosol preparation identical in appearance
Study: 31358032
Drug: PCT-based algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT-based algorithm to guide antibiotic use
Study: 17596795
Drug: Hib-DPT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-DPT vaccine (3 doses)
Study: 17596795
Drug: Hib-DPT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-DPT vaccine (2 doses)
Study: 17596795
Drug: Hib-DPT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-DPT vaccine
Study: 8799530
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg microenema
Study: 8799530
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg as a 60 min i.v. continuous infusion
Study: 8799530
Drug: Suppositories
Normalized name: Tucks Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppositories
Study: 1600971
Drug: Stepdown regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepdown regimen of propofol (10 mg kg‐1 h‐1 for 10 min, 8 mg kg‐1 h‐1 for the next 10 min, 6 mg kg‐1 h‐1 thereafter)
Study: 1600971
Drug: Steady rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steady rate infusion of propofol (6 mg kg‐1 h‐1)
Study: 1600971
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Stepdown and Steady rate infusion)
Study: 31466813
Drug: NCHT (Neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCHT (Neoadjuvant Chemohormonal Therapy)
Study: 31466813
Drug: NHT (Neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHT (Neoadjuvant Hormonal Therapy)
Study: 31466813
Drug: No-NT (No
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-NT (No Neoadjuvant Therapy)
Study: 25171552
Drug: Curcuminoids (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (1500 mg/day) + piperine (15 mg/day)
Study: 25913052
Drug: Triamcinolone ointment
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone ointment CIC
Study: 25913052
Drug: Contractubex ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contractubex ointment CIC
Study: 16868325
Drug: Nitroglycerin patch
Normalized name: Nitroglycerin Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patch (0.2 mg/h)
Study: 16868325
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (adhesive patch without active ingredient)
Study: 10962867
Drug: Ceftibuten 400
Normalized name: ceftibuten 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten 400 mg od for seven days
Study: 10962867
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g/day i.v. for a total of 10 days
Study: 8853769
Drug: Amoxycillin suspension
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin suspension given pre-prandially
Study: 8853769
Drug: Amoxycillin suspension
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin suspension given post-prandially
Study: 1377333
Drug: Paracetamol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (3 x 1000 mg over 8 h)
Study: 6725527
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg orally)
Study: 6725527
Drug: Metoclopramide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (20 mg orally) plus Bromocriptine
Study: 6725527
Drug: Domperidone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (20 mg orally) plus Bromocriptine
Study: 22388713
Drug: Head orthesis
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head orthesis therapy
Study: 18693659
Drug: Bupivacaine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (2.5 mg)
Study: 8517061
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g vigabatrin for 2 months
Study: 8517061
Drug: titrated optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: titrated optimal dosage vigabatrin for another 2 months
Study: 3481814
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ANG II and NA infusion
Study: 29164797
Drug: sacubitril/valsartan (LCZ696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan (LCZ696) 200 mg twice per day, initiated and up-titrated over 3 or 6 weeks
Study: 29164797
Drug: Gradual up-titration
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual up-titration (6 weeks) of sacubitril/valsartan
Study: 29164797
Drug: sacubitril/valsartan (LCZ696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan (LCZ696) 200 mg twice per day
Study: 19366965
Drug: Ranirestat 20
Normalized name: Ranirestat
DrugBank: Ranirestat (DB05327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranirestat 20 mg/day
Study: 19366965
Drug: Ranirestat 40
Normalized name: Ranirestat
DrugBank: Ranirestat (DB05327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranirestat 40 mg/day
Study: 16935343
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly defined, but implied as the comparison between the two doses)
Study: 15293170
Drug: Non-invasive ventilation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive ventilation (NIV) applied for at least six hours per day in addition to standard COPD treatment.
Study: 15293170
Drug: Standard COPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard COPD treatment (Control group).
Study: 2813482
Drug: Cocaine infusion
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine infusion after bolus loading doses
Study: 2813482
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion after bolus loading doses
Study: 4586044
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aerosol (400 mug daily, intranasally)
Study: 31579978
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Silymarin and Doxycycline
Study: 25327537
Drug: Tapered implants
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tapered implants (test group)
Study: 25327537
Drug: Cylindrical implants
Normalized name: Imperata cylindrica root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cylindrical implants (control group)
Study: 21505349
Drug: LOS100 (Losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOS100 (Losartan 100 mg q.d.)
Study: 21505349
Drug: LOS200 (Losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOS200 (Losartan 100 mg b.i.d.)
Study: 21505349
Drug: LOS100 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOS100 + LIS20 (Losartan 100 mg q.d. + Lisinopril 20 mg q.d.)
Study: 17224949
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% cyclosporine A in preservative-free artificial tears
Study: 14499682
Drug: 0.5mg dutasteride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg dutasteride and 0.4mg tamsulosin for 24 weeks followed by dutasteride monotherapy
Study: 14499682
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of tamsulosin therapy at week 24
Study: 9113009
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.8-1.1 g/kg daily adjusted for age)
Study: 7690093
Drug: Atenolol 300
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 300 mg
Study: 3527810
Drug: Treatment within
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment within 6 hours of chest pain onset
Study: 3527810
Drug: Treatment 6
Normalized name: Earwax Treatment 6.5% Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 6 to 12 hours after chest pain onset
Study: 24500147
Drug: Dietary calcium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary calcium intake (1000 mg Ca)
Study: 24500147
Drug: Risk alleles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk alleles from a score of 6 WC-associated SNPs with dietary calcium intake (1000 mg Ca)
Study: 20929598
Drug: Pranlukast (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (225 mg, b.i.d.)
Study: 20929598
Drug: Salmeterol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (100 μg, b.i.d.)
Study: 18356628
Drug: Lipid-lowering drug
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering drug therapy
Study: 18356628
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fibrate or nicotinic acid with LDL cholesterol-lowering drug
Study: 18356628
Drug: LDL cholesterol-lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL cholesterol-lowering drug therapy
Study: 16038024
Drug: Oral Xeloda
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Xeloda 1,000 mg/m2 administered twice daily from d 1 to 14
Study: 16038024
Drug: Calcium folinate
Normalized name: Calcium folinate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium folinate (CF) 200 mg/m2 as a 2-h intravenous infusion followed by 5-FU 600 mg/m2 intravenously for 4-6 h on d 1-5
Study: 12447029
Drug: Fluoxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (up to 60 mg/day for 6 weeks, then up to 80 mg/day for 8 weeks)
Study: 12447029
Drug: Fluoxetine responders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine responders (n = 11)
Study: 10337457
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of fermented and unfermented aqueous extracts of Viscum album L. (Iscador Qu Spezial and Viscum album QuFrF)
Study: 10337457
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of fermented and unfermented aqueous extracts of Viscum album L.
Study: 9110055
Drug: Doxazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1 mg daily, increased to a maximum of 16 mg daily)
Study: 1943500
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (6 g per day)
Study: 7015693
Drug: VM-26 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM-26 (30 mg/m2 iv for 5 days with 7-14 day intervals)
Study: 7015693
Drug: VM-26 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM-26 (50 mg/m2 two injections a week for 4-6 weeks)
Study: 28807367
Drug: Platinum therapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum therapy for OCCC
Study: 28807367
Drug: Platinum therapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum therapy for SOC